Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Current Deferred Revenue (2018)

Historic Current Deferred Revenue for Anika Therapeutics (ANIK) over the last 7 years, with Q3 2018 value amounting to $52000.0.

  • Anika Therapeutics' Current Deferred Revenue changed N/A to $52000.0 in Q3 2018 from the same period last year, while for Sep 2018 it was $52000.0, marking a year-over-year change of. This contributed to the annual value of $24510.0 for FY2014, which is 9890.35% down from last year.
  • According to the latest figures from Q3 2018, Anika Therapeutics' Current Deferred Revenue is $52000.0.
  • Over the past 5 years, Anika Therapeutics' Current Deferred Revenue peaked at $139535.0 during Q1 2015, and registered a low of $12885.0 during Q3 2014.
  • Moreover, its 3-year median value for Current Deferred Revenue was $35938.0 (2015), whereas its average is $48299.0.
  • In the last 5 years, Anika Therapeutics' Current Deferred Revenue crashed by 9898.8% in 2014 and then soared by 20064.42% in 2015.
  • Over the past 3 years, Anika Therapeutics' Current Deferred Revenue (Quarter) stood at $24510.0 in 2014, then surged by 38.51% to $33948.0 in 2015, then soared by 53.18% to $52000.0 in 2018.
  • Its last three reported values are $52000.0 in Q3 2018, $74000.0 for Q2 2018, and $33948.0 during Q3 2015.